This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/resource/domain/vavai/subjekt/
n3http://linked.opendata.cz/ontology/domain/vavai/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F26475821%3A_____%2F11%3A%230000125%21RIV12-MZ0-26475821/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F26475821%3A_____%2F11%3A%230000125%21RIV12-MZ0-26475821
rdf:type
n3:Vysledek skos:Concept
dcterms:description
KRAS mutations can be found in 15 to 25% of lung cancers, frequently in adenocarcinomas and their presence is associated with smoking. The role of KRAS mutations in biological targeted therapy by EGFR inhibitors is ambiguous. While some reports clearly assigned mutated KRAS as negative prognostic factor and negative predictor, others did not confirm such notion. In our work we aimed to elucidate the role of specific type of KRAS mutation in outcome of patients with advanced NSCLC threated with EGFR-TKI therapy. KRAS mutations can be found in 15 to 25% of lung cancers, frequently in adenocarcinomas and their presence is associated with smoking. The role of KRAS mutations in biological targeted therapy by EGFR inhibitors is ambiguous. While some reports clearly assigned mutated KRAS as negative prognostic factor and negative predictor, others did not confirm such notion. In our work we aimed to elucidate the role of specific type of KRAS mutation in outcome of patients with advanced NSCLC threated with EGFR-TKI therapy.
dcterms:title
The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors. The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors.
skos:prefLabel
The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors. The Role of Specific KRAS Mutation Types in Response to Treatment by EGFR Inhibitors.
skos:notation
RIV/26475821:_____/11:#0000125!RIV12-MZ0-26475821
n3:predkladatel
n8:ico%3A26475821
n4:aktivita
n14:P
n4:aktivity
P(NS9718)
n4:dodaniDat
n15:2012
n4:domaciTvurceVysledku
n6:7377061 n6:2689677 n6:6636365
n4:druhVysledku
n17:O
n4:duvernostUdaju
n7:S
n4:entitaPredkladatele
n10:predkladatel
n4:idSjednocenehoVysledku
227509
n4:idVysledku
RIV/26475821:_____/11:#0000125
n4:jazykVysledku
n9:eng
n4:klicovaSlova
KRAS mutation; treatment; EGFR inhibitors
n4:klicoveSlovo
n5:treatment n5:EGFR%20inhibitors n5:KRAS%20mutation
n4:kontrolniKodProRIV
[959EF12D6FAF]
n4:obor
n13:FD
n4:pocetDomacichTvurcuVysledku
3
n4:pocetTvurcuVysledku
5
n4:projekt
n16:NS9718
n4:rokUplatneniVysledku
n15:2011
n4:tvurceVysledku
Benšová, Lucie Minárik, Marek Belšánová, Barbora